These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 24126392)
1. Rapid progression of Graves' ophthalmopathy despite the administration of thiamazole. Katsuyama T; Takeda M; Otsuka F; Toma K; Inagaki K; Sada KE; Mimura Y; Ogura T; Makino H Intern Med; 2013; 52(20):2317-20. PubMed ID: 24126392 [TBL] [Abstract][Full Text] [Related]
2. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Laurberg P; Berman DC; Andersen S; Bülow Pedersen I Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677 [TBL] [Abstract][Full Text] [Related]
3. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy? Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069 [TBL] [Abstract][Full Text] [Related]
4. An infant case of Graves' disease with ophthalmopathy. Kubo T; Shimizu J; Furujo M; Takeuchi A; Yoshioka-Iwaso H; Eguchi N; Fukuhara S; Koyama T; Kanadani T; Shiraga H; Oshima K Endocr J; 2005 Oct; 52(5):647-50. PubMed ID: 16284447 [TBL] [Abstract][Full Text] [Related]
5. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis. Le Moli R; Russo M; Malandrino P; Vella V; Belfiore A; Frasca F Hormones (Athens); 2021 Mar; 20(1):161-165. PubMed ID: 32500462 [TBL] [Abstract][Full Text] [Related]
6. Sight-Threatening Graves' Ophthalmopathy during the Third Trimester of Pregnancy: A Case Report. Sakurai K; Inoue T; Niitsuma S; Sato R; Takahashi K; Arihara Z Tohoku J Exp Med; 2020 Dec; 252(4):321-327. PubMed ID: 33268601 [TBL] [Abstract][Full Text] [Related]
7. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report. Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094 [TBL] [Abstract][Full Text] [Related]
8. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism. Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602 [No Abstract] [Full Text] [Related]
9. Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report. Abramavicius S; Velickiene D; Kadusevicius E Medicine (Baltimore); 2017 Sep; 96(39):e8159. PubMed ID: 28953662 [TBL] [Abstract][Full Text] [Related]
10. [The influence of hyperthyroidism and glucocorticosteroid treatment on bone metabolism in patients with Graves' disease and ophthalmopathy]. Kaźmierczyk-Puchalska A; Kulig G; Krzyzanowska-Swiniarska B; Pilarska K Endokrynol Pol; 2005; 56(3):259-64. PubMed ID: 16350719 [TBL] [Abstract][Full Text] [Related]
11. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255 [TBL] [Abstract][Full Text] [Related]
12. Intravenous cyclophosphamide pulse therapy is effective for refractory Graves' ophthalmopathy. Tanikawa T; Okada Y; Tanaka Y J UOEH; 2006 Jun; 28(2):185-91. PubMed ID: 16780226 [TBL] [Abstract][Full Text] [Related]
13. [Case of Graves' disease presenting only with rapid consciousness disturbance]. Nagaishi A; Yukitake M; Kuroda Y Rinsho Shinkeigaku; 2006 Apr; 46(4):285-7. PubMed ID: 16768098 [TBL] [Abstract][Full Text] [Related]
14. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337 [TBL] [Abstract][Full Text] [Related]
15. A treatment strategy for Graves' orbitopathy. Marcocci C; Pinchera A; Marinò M Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):430-6. PubMed ID: 17452970 [TBL] [Abstract][Full Text] [Related]
16. Evans' syndrome associated with Graves' disease. Yashiro M; Nagoshi H; Kasuga Y; Isobe H; Kitajima S; Nakagawa T; Ohshima J; Ide K; Someya K; Saito N Intern Med; 1996 Dec; 35(12):987-90. PubMed ID: 9031001 [TBL] [Abstract][Full Text] [Related]
17. Effect of Addition of Thyroxine in the Treatment of Graves' Disease: A Systematic Review. Li J; Bai L; Wei F; Wei M; Xiao Y; Yan W; Wei J Front Endocrinol (Lausanne); 2020; 11():560157. PubMed ID: 33569041 [TBL] [Abstract][Full Text] [Related]
18. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Krassas GE; Segni M; Wiersinga WM Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172 [TBL] [Abstract][Full Text] [Related]
19. Severe graves ophthalmopathy accompanied by HTLV-1-associated uveitis (HAU) and anti-neutrophil cytoplasmic antibody-related vasculitis: a case report and a review of the literature of HAU with Graves disease. Sarui H; Sano A; Maruyama T; Nakashima K; Takeda N; Yasuda K Am J Med Sci; 2002 Aug; 324(2):109-14. PubMed ID: 12186105 [TBL] [Abstract][Full Text] [Related]